- Current report filing (8-K)
July 27 2012 - 5:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported) July 24, 2012
ACELRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
DELAWARE
|
|
001-35068
|
|
41-2193603
|
(State of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
351 Galveston Drive
Redwood City, CA 94063
(Address of principal executive offices and zip
code)
Registrants telephone number, including area code: (650) 216-3500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
The 2012 Annual Meeting of Stockholders (the Annual Meeting) of AcelRx Pharmaceuticals, Inc. (the Company) was held on July 24, 2012. Proxies for the Annual Meeting were
solicited by the Board of Directors of the Company (the Board) pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Boards solicitation. There were
22,625,000 shares of common stock entitled to vote at the Annual Meeting. A total of 18,694,714 shares were represented at the Annual Meeting in person or by proxy. The final votes on the proposals presented at the Annual Meeting were as follows:
Proposal No. 1
Guy P. Nohra, Thomas A. Schreck and Mark G. Edwards were elected as directors to hold office until the 2015 Annual Meeting of Stockholders by the following vote:
|
|
|
|
|
|
|
Nominee
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
Guy P. Nohra
|
|
16,889,002
|
|
200
|
|
1,805,512
|
Thomas A. Schreck
|
|
16,888,608
|
|
594
|
|
1,805,512
|
Mark G. Edwards
|
|
16,889,202
|
|
0
|
|
1,805,512
|
In addition to the directors elected above, Stephen J. Hoffman, Ph.D., M.D., Richard A. King and Pamela
P. Palmer, M.D., Ph.D. will continue to serve as directors until the 2013 Annual Meeting of Stockholders and until their successors are elected and have qualified, or until their earlier death, resignation or removal. Howard B. Rosen and Mark Wan
will continue to serve as directors until the 2014 Annual Meeting of Stockholders and until their successors are elected and have qualified, or until their earlier death, resignation or removal.
Proposal No. 2
The
selection by the Audit Committee of the Board of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2012 was ratified by the following vote:
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
18,559,957
|
|
134,757
|
|
0
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 25, 2012
|
|
|
|
|
ACELRX PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ James H. Welch
|
Name:
|
|
James H. Welch
|
Title:
|
|
Chief Financial Officer
|
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Oct 2023 to Oct 2024